TAK-755-2001 A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP)
Clinical Trial Grant
Administered By
Medicine, Hematology
Awarded By
Takeda Development Center Americas, Inc
Start Date
March 15, 2023
End Date
December 15, 2026
Administered By
Medicine, Hematology
Awarded By
Takeda Development Center Americas, Inc
Start Date
March 15, 2023
End Date
December 15, 2026